News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
754,525 Results
Type
Article (46596)
Company Profile (244)
Press Release (707673)
Multimedia
Podcasts (158)
Webinars (22)
Section
Business (238750)
Career Advice (2053)
Deals (36233)
Drug Delivery (153)
Drug Development (84708)
Employer Resources (175)
FDA (17144)
Job Trends (15268)
News (354909)
Policy (33517)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (4)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (6)
Academia (2742)
Academic (1)
Accelerated approval (60)
ADA (46)
Adcomms (39)
Allergies (200)
Alliances (50947)
ALS (235)
Alzheimer's disease (1966)
Antibody-drug conjugate (ADC) (573)
Approvals (17581)
Artificial intelligence (787)
ASCO (335)
Autoimmune disease (371)
Automation (67)
Bankruptcy (369)
Best Places to Work (11851)
BIO (74)
BIOSECURE Act (23)
Biosimilars (251)
Biotechnology (167)
Bladder cancer (216)
Brain cancer (84)
Breast cancer (852)
Cancer (6684)
Cardiovascular disease (549)
Career advice (1750)
Career pathing (45)
CAR-T (394)
CDC (62)
Celiac Disease (3)
Cell therapy (1091)
Cervical cancer (58)
Clinical research (74061)
Collaboration (2385)
Commercialization (1)
Company closure (7)
Compensation (1587)
Complete response letters (106)
COVID-19 (2843)
CRISPR (128)
C-suite (1328)
Cystic fibrosis (168)
Data (8957)
Decentralized trials (3)
Denatured (39)
Depression (195)
Dermatology (105)
Diabetes (704)
Diagnostics (7198)
Digital health (66)
Diversity (13)
Diversity, equity & inclusion (45)
Drug discovery (393)
Drug pricing (220)
Drug shortages (34)
Duchenne muscular dystrophy (333)
Earnings (93276)
Editorial (76)
Employer branding (21)
Employer resources (157)
Events (124062)
Executive appointments (1183)
FDA (21336)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (22)
Frontotemporal dementia (36)
Funding (1964)
Gene editing (276)
Generative AI (68)
Gene therapy (868)
GLP-1 (1198)
Government (4895)
Grass and pollen (6)
Guidances (423)
Healthcare (19676)
Hematology (198)
HIV (97)
Huntington's disease (72)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (116)
Immunology and inflammation (339)
Immuno-oncology (117)
Indications (227)
Infectious disease (3226)
Inflammatory bowel disease (237)
Inflation Reduction Act (14)
Influenza (145)
Intellectual property (329)
Interviews (323)
IPO (16932)
IRA (52)
Job creations (3715)
Job search strategy (1444)
JPM (69)
Kidney cancer (24)
Labor market (113)
Layoffs (626)
Leadership (45)
Legal (8062)
Liver cancer (108)
Longevity (37)
Lung cancer (879)
Lymphoma (492)
Machine learning (68)
Management (61)
Manufacturing (1225)
Marketing (7)
MASH (228)
Medical affairs (1)
Medical device (14271)
Medtech (14456)
Mergers & acquisitions (20648)
Metabolic disorders (1787)
mRNA (262)
Multiple sclerosis (205)
NASH (19)
Neurodegenerative disease (522)
Neuropsychiatric disorders (121)
Neuroscience (3714)
Neurotech (1)
NextGen: Class of 2026 (6735)
Non-profit (4647)
Now hiring (83)
Obesity (831)
Opinion (321)
Ovarian cancer (246)
Pain (287)
Pancreatic cancer (368)
Parkinson's disease (415)
Partnered (37)
Patents (669)
Patient recruitment (823)
Peanut (69)
People (61171)
Pharmaceutical (52)
Pharmacy benefit managers (33)
Phase 1 (23125)
Phase 2 (32571)
Phase 3 (24281)
Pipeline (10332)
Policy (360)
Postmarket research (2729)
Preclinical (9845)
Press Release (69)
Prostate cancer (355)
Psychedelics (74)
Radiopharmaceuticals (373)
Rare diseases (1315)
Real estate (6083)
Recruiting (73)
Regulatory (26730)
Reports (57)
Research institute (2542)
Resumes & cover letters (357)
Rett syndrome (47)
RNA editing (29)
RSV (92)
Schizophrenia (190)
Series A (337)
Series B (249)
Service/supplier (7)
Sickle cell disease (132)
Special edition (32)
Spinal muscular atrophy (181)
Sponsored (49)
Startups (3792)
State (2)
Stomach cancer (21)
Supply chain (137)
Tariffs (92)
The Weekly (116)
Vaccines (1211)
Venture capital (129)
Weight loss (547)
Women's health (143)
Worklife (22)
Date
Today (94)
Last 7 days (422)
Last 30 days (2091)
Last 365 days (31620)
2026 (17596)
2025 (31270)
2024 (36195)
2023 (41049)
2022 (52296)
2021 (56823)
2020 (55095)
2019 (47633)
2018 (35954)
2017 (33032)
2016 (32437)
2015 (38444)
2014 (32164)
2013 (27177)
2012 (29331)
2011 (30045)
2010 (28196)
Location
Africa (773)
Alabama (95)
Alaska (7)
Arizona (374)
Arkansas (14)
Asia (41482)
Australia (6875)
California (14406)
Canada (4050)
China (1612)
Colorado (620)
Connecticut (630)
Delaware (442)
Europe (92011)
Florida (2199)
Georgia (465)
Hawaii (3)
Idaho (64)
Illinois (1186)
India (105)
Indiana (646)
Iowa (25)
Japan (618)
Kansas (140)
Kentucky (53)
Louisiana (60)
Maine (78)
Maryland (1700)
Massachusetts (10456)
Michigan (378)
Minnesota (770)
Mississippi (6)
Missouri (164)
Montana (34)
Nebraska (30)
Nevada (152)
New Hampshire (89)
New Jersey (3775)
New Mexico (34)
New York (3831)
North Carolina (1869)
North Dakota (11)
Northern California (7272)
Ohio (429)
Oklahoma (26)
Oregon (41)
Pennsylvania (2851)
Puerto Rico (31)
Rhode Island (52)
South America (1139)
South Carolina (90)
South Dakota (2)
Southern California (5702)
Tennessee (235)
Texas (2324)
United States (51044)
Utah (426)
Vermont (2)
Virginia (348)
Washington D.C. (84)
Washington State (1143)
West Virginia (4)
Wisconsin (142)
Wyoming (2)
754,525 Results for "neuropore therapies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Niowave, Inc. and Ratio Therapeutics Sign Supply Agreement for Actinium-225 to Advance Targeted Alpha Therapies
June 17, 2026
·
3 min read
M&A
Merck KGaA inks $11B Bio-Techne buyout to expand into cell therapy production
The company is “especially excited” about an immune cell therapy manufacturing technology included in the deal, a Merck KGaA executive said.
June 26, 2026
·
2 min read
·
Nick Paul Taylor
Press Releases
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
July 13, 2026
·
5 min read
Press Releases
Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision Radionuclide Therapy™
July 6, 2026
·
3 min read
Press Releases
OS Therapies Appoints Dr. Craig Eagle to Board of Directors
• Company secures $10 million line of credit supported by OS Therapies UK tax credits
July 2, 2026
·
7 min read
Press Releases
CoRegen, Inc. Receives FDA Clearance to Advance CRG-150 into Phase 1/2a Clinical Trials, Pioneering a New Frontier in Cell Therapy for Multiple Solid Tumor Types
July 7, 2026
·
4 min read
Neuroscience
UniQure’s chronic epilepsy gene therapy ‘should be on investors’ radar’
As uniQure prepares its closely watched Huntington’s disease gene therapy for FDA review, the biotech is also making waves in chronic epilepsy with another gene therapy that Stifel says is off to a “promising start.”
June 22, 2026
·
3 min read
·
Tristan Manalac
Press Releases
La Jolla Labs, Inc. Announces First Patient Treated with Custom Antisense Therapy GBFsen for familial ALS
April 30, 2026
·
1 min read
Press Releases
Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision Radionuclide Therapy™
June 7, 2026
·
3 min read
Press Releases
Osel Inc. and March of Dimes Announce Groundbreaking Phase 2b Trial of Microbiome-based Therapy Targeting Preterm Birth Prevention
May 13, 2026
·
7 min read
1 of 75,453
Next
